Du är här


Oxford Immunotec: Oxford Immunotec Schedules Fourth Quarter and Full Year 2015 Earnings Release and Conference Call for March 1, 2016

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 18, 2016 (GLOBE NEWSWIRE)
-- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage
diagnostics company focused on developing and commercializing proprietary
tests for the management of immune-regulated conditions, today announced that
it plans to release fourth quarter and full year 2015 financial results prior
to market open on Tuesday, March 1, 2016. Dr. Peter Wrighton-Smith, Chief
Executive Officer, and Rick Altieri, Chief Financial Officer, will host a
conference call to review the Company's results at 8:00 a.m. Eastern Time the
same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial (855) 363-5047
for United States callers and +1 (484) 365-2897 for international callers and
reference confirmation code 55316515, approximately ten minutes prior to
start time. To access the live audio webcast or subsequent archived
recording, visit the Investor Relations section of Oxford Immunotec's website
at www.oxfordimmunotec.com. The replay will be available on the Company's
website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company
focused on developing and commercializing proprietary tests for the
management of immune-regulated conditions. The Company's first product is
the T-SPOT®.TB
test, which is used to test for tuberculosis infection. The T-SPOT.TB
test has been approved for sale in over 50 countries, including the United
States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The T-SPOT.CMV
test and the T-SPOT.PRT
test are the Company's second and third products and part of a series of
products intended for the transplantation market. In addition to these three
products, the Company has an additional six active development programs, each
of which leverages our T cell, B cell and innate immune measuring technology.
The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.


For Media Inquiries:

Caroline Crawley

Oxford Immunotec
Tel: +44 1235 442796

For Investor Inquiries:

Rick Altieri

Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.